MeiraGTx Holdings plc, an integrated clinical stage gene therapy company, develops various gene therapy products for the lives of patients
suffering from acquired and inherited disorders. The company focuses on various areas of unmet medical need comprising inherited retinal diseases, xerostomia, and neurodegenerative diseases. It has four ongoing clinical programs, including AAV-RPE65, which is in Phase I 002FII clinical trials for the treatment of RPE65-deficiency in adult and pediatric patients; AAV-RPGR that is in Phase I 002FII clinical trials to treat x-linked retinitis pigmentosa in adult and pediatric patients; AAV-CNGB3 that is in Phase I 002FII clinical trials for the treatment of achromatopsia in adult and pediatric patients; and AAV-AQP1, which is in Phase I 002FII clinical trials for the treatment of patients with grade 2 or 3 radiation-induced xerostomia. The company also has a pipeline of preclinical and research programs in other indications. MeiraGTx Holdings plc has a research collaboration and evaluation agreement with Janssen Pharmaceuticals, Inc. the company was founded in 2015 and is based in New York, New York. The company trades on NASDAQ exchange. The company headquarter is located in New York, NY. The company was established in the 2015.
| Ticker | MGTX |
| Long Name | MeiraGTx Holdings plc |
| Short Name | MeiraGTx |